# A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

> **NCT01464112** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 18 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** JNJ-2641585 / VELCADE / Dexamethasone

## Key facts

- **NCT ID:** NCT01464112
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-16
- **Primary completion:** 2013-11-19
- **Final completion:** 2013-11-19
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01464112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01464112, "A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01464112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*